Ulobetasol
- Generic Name
- Ulobetasol
- Brand Names
- Bryhali, Duobrii, Lexette, Ultravate, Ultravate X Ointment
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27ClF2O4
- CAS Number
- 98651-66-2
- Unique Ingredient Identifier
- 9P6159HM7T
- Background
Ulobetasol is a highly potent corticosteroid. It is structurally related to clobetasol. Due to its high potency, it is mainly prescribed in the treatment of severe plaque psoriasis and corticosteroid responsive dermatoses.
Ulobetasol was granted FDA approval on 17 December 1990.
- Indication
Ulobetasol cream and ointment are indicated in the treatment of inflammatory and pruritic corticosteroid responsive dermatoses. Ulobetasol lotion is indicated in the treatment of plaque psoriasis.
- Associated Conditions
- Psoriasis Vulgaris (Plaque Psoriasis), Corticosteroid responsive, Inflammatory Dermatosis, Corticosteroid responsive, pruritic Dermatosis
Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis
- Conditions
- Psoriasis Vulgaris
- Interventions
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Dermatology Consulting Services, PLLC
- Target Recruit Count
- 10
- Registration Number
- NCT06042647
- Locations
- 🇺🇸
Dermatology Consulting Services, PLLC, High Point, North Carolina, United States
Duobrii Treatment of Acne Keloidalis Nuchae (AKN)
- Conditions
- Acne Keloidalis NuchaeAKN
- Interventions
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 30
- Registration Number
- NCT05608499
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.
- Conditions
- Plaque Psoriasis
- Interventions
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- Taro Pharmaceuticals USA
- Target Recruit Count
- 402
- Registration Number
- NCT05282771
- Locations
- 🇺🇸
Catawba Research, LLC, Charlotte, North Carolina, United States
Efficacy and Safety of Sorilux in Maintenance Treatment of Moderate Type Plaque Psoriasis
- Conditions
- Plaque Psoriasis
- Interventions
- First Posted Date
- 2020-09-30
- Last Posted Date
- 2020-11-20
- Lead Sponsor
- Skin Sciences, PLLC
- Target Recruit Count
- 30
- Registration Number
- NCT04571151
- Locations
- 🇺🇸
Skin Sciences, PLLC, Louisville, Kentucky, United States
Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Mayne Pharma International Pty Ltd
- Target Recruit Count
- 24
- Registration Number
- NCT03992261
- Locations
- 🇵🇱
Investigative Site 3, Krakow, Poland
🇵🇱Investigative Site 5, Tarnów, Poland
🇬🇪Investigative Site 10, Tbilisi, Georgia
Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Plaque Psoriasis
- First Posted Date
- 2017-10-02
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Registration Number
- NCT03298581
Evaluation of Adrenal Suppression Potential and Pharmacokinetics of Halobetasol Lotion 0.05%
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2021-12-07
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 16
- Registration Number
- NCT03212963
- Locations
- 🇺🇸
Power MD Clinical Research Institute, Hialeah, Florida, United States
🇺🇸MediSearch Clinical Trials, Saint Joseph, Missouri, United States
🇺🇸First OC Dermatology, Fountain Valley, California, United States
Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2017-06-09
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 94
- Registration Number
- NCT03058744
- Locations
- 🇺🇸
Valeant Site 05, Encino, California, United States
🇺🇸Valeant Site 06, New York, New York, United States
🇺🇸Valeant Site 01, San Diego, California, United States
Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2016-05-27
- Last Posted Date
- 2020-08-27
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT02785185
- Locations
- 🇺🇸
Valeant Site 10, Beverly Hills, California, United States
🇺🇸Valeant Site 09, Carlsbad, California, United States
🇺🇸Valeant Site 11, North Miami Beach, Florida, United States
Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2016-05-27
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 154
- Registration Number
- NCT02785172
- Locations
- 🇺🇸
Valeant Site 03, San Diego, California, United States
🇺🇸Valeant Site 07, Fridley, Minnesota, United States
🇺🇸Valeant Site 06, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.